MannKind Corporation (NASDAQ:MNKD), has been given an average recommendation of “Hold” by the nine analysts that are presently covering the company, StockRatingsNetwork.com reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $9.56. MannKind Corporation (NASDAQ:MNKD), weekly performance is -2.64%. On last trading day company shares ended up $10.32. Analysts mean target price for the company is $9.06. MannKind Corporation (NASDAQ:MNKD), distance from 50-day simple moving average (SMA50) is 23.40%.
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, announced that it has received CE Mark approval for its new Visian ICL Preloaded System. The Preloaded ICL provides a number of benefits to both surgeons and their patients during the delivery of STAAR’s Implantable Collamer Lens (ICL) into the eye. STAAR plans the official launch of the Preloaded System at the Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in London during September 2014. STAAR Surgical Company (NASDAQ:STAA), fell 11.25% in last trading session and ended the day on $14.91. STAA, Gross Margin is 69.20% and its return on assets is -2.50%. STAAR Surgical Company (NASDAQ:STAA), quarterly performance is -21.40%.
Equities researchers at Jefferies Group increased their price target on shares of Arrowhead Research Corp (NASDAQ:ARWR), from $29.00 to $30.00 in a research report issued on Friday. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price suggests a potential upside of 99.34% from the company’s current price. Arrowhead Research Corp (NASDAQ:ARWR), shares moved down 5.10% in last trading session and was closed at $13.58, while trading in range of $13.54 – 14.52. Arrowhead Research Corp (NASDAQ:ARWR), year to date (YTD) performance is 25.16%.
On June 27, 2014, Karyopharm Therapeutics Inc (NASDAQ:KPTI), announced the pricing of its underwritten public offering of 2.65 million shares of its common stock at a price of $42.50 per share before underwriting discounts. Karyopharm Therapeutics Inc (NASDAQ:KPTI), ended the last trading day at $44.15. Company weekly volatility is calculated as 6.79% and price to cash ratio as 9.07. Karyopharm Therapeutics Inc (NASDAQ:KPTI), showed a negative weekly performance of 6.72%.
On May 30, 2014, Heat Biologics Inc (NASDAQ:HTBX), announced that its Dose Escalation Committee has approved the expansion of the first cohort to full enrollment in its ongoing Phase 1/2 study of HS-410 for the treatment of bladder cancer. The committee unanimously agreed to expand the cohort to the full nine patients without delay. Heat Biologics Inc (NASDAQ:HTBX), weekly performance is 0.78%. On last trading day company shares ended up $5.17. Analysts mean target price for the company is $20.00. Heat Biologics Inc (NASDAQ:HTBX), distance from 50-day simple moving average (SMA50) is 8.22%.